DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Conditions: HER2-positive Breast Cancer Interventions: Drug: DP303c; Drug: trastuzumab emtansine Sponsors: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06313086

Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials